*

Company to delist from London, maintain Nasdaq listing

*

Indivior's ( INDV ) revenue heavily reliant on US market

*

London struggling to attract major IPOs despite rule

changes

(Adds shares in paragraph 3, background throughout)

June 2 (Reuters) - Pharma firm Indivior ( INDV ) said on

Monday it would cancel its secondary listing on the London Stock

Exchange, effective July 25, maintaining its primary listing on

the Nasdaq to reduce costs and better align with its

U.S.-centric business.

The company, known for its opioid addiction treatment, joins

a growing number of firms delisting from London, as lower

valuations and weak investor appetite continue to drive firms

toward U.S. markets.

Shares in the company fell 1% in early trade.

Indivior ( INDV ), which listed in London in 2014 after being spun

off from Reckitt Benckiser ( RBGPF ), has seen its shares fall

more than 60% from a 2018 peak.

It shifted its primary listing to the U.S. last year and

said the London delisting would streamline operations. Indivior ( INDV )

follows other firms, including gambling group Flutter,

in shifting primary listings away from the UK market.

London, meanwhile, continues to struggle to revive its

appeal as a listing destination despite last year's efforts to

overhaul listing rules and revive its capital markets.

Chinese fast-fashion retailer Shein chose Hong Kong over

London for its IPO, highlighting the continued difficulty in

attracting major IPOs, Reuters reported last month.

A string of London-listed firms, including DS Smith and

Darktrace, have also delisted following takeovers in recent

months.

Indivior ( INDV ) said over 80% of its revenue now comes from the

U.S., with the Nasdaq accounting for about 75% of

recent trading volumes.

The delisting follows a management shake-up, with David

Wheadon appointed chair and Joe Ciaffoni CEO this year. In

December, the CFO stepped down after pressure from top

shareholder Oaktree Capital.

In February, the drugmaker forecast a 17% drop in 2025 net

revenue, partly citing weak sales of its film-form

medication-assisted therapy for opiate addiction.